)
Nanoform Finland (NANOFH) investor relations material
Nanoform Finland CMD 2025 Presentation summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Strategic vision and business targets for 2026–2030
Aims to break technological barriers in both small and large molecule drug development using CESS® for small molecules and BioLine for biologics, supporting the industry shift from IV to subcutaneous delivery.
Targets over 300 non-GMP projects and more than 30 GMP projects by 2030, with three nanoformed medicines launched by that year.
Sets ambitious financial goals: revenue exceeding €30 million, cumulative milestones over €30 million, and income growth above 50% CAGR from 2026–2030, with EBIT margin above 30%.
Cost growth is projected to remain below 5% CAGR due to prior investments in manufacturing scale-up and digital infrastructure.
Industry context and technology differentiation
Despite rising global pharma R&D spending, the number of new FDA drug approvals has remained flat, highlighting the need for innovative solutions.
Nanoform’s technology addresses low transition rates from preclinical to GMP projects, aiming to reach industry standards by 2030.
The CESS® process enables efficient, scalable nanoforming, with significant improvements in throughput and cost since 2021.
BioLine technology produces highly stable, high-concentration biologic suspensions, validated by large pharma partners for injectable and pulmonary delivery.
Product pipeline and partnerships
Pipeline includes nanoenzalutamide (prostate cancer), nanoapalutamide, nanoencorafenib (melanoma/colorectal cancer), and GLIORA (glioma), with launches targeted between 2028–2033.
Strategic partnerships with Helm Pharmaceuticals, Brafmed, and Revio Therapeutics support product development, regulatory submissions, and commercialization.
Nanoenzalutamide leverages a novel polymer-embedded nanoparticle platform to overcome existing patent and formulation hurdles, enabling smaller, patient-centric tablets.
GLIORA, a long-acting intra-tumoral hydrogel for glioma, combines nanoformed APIs for synergistic local therapy, with a de-risked development plan and strong IP protection.
Next Nanoform Finland earnings date
Next Nanoform Finland earnings date
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
Frequently asked questions
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage
)
)